[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100264080":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Arizona","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Blood Draw",null,"A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin\u002FPF4 antibodies (controls); (2) participants without HIT testing positive for heparin\u002FPF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin\u002FPF4 antibodies (HIT cases).",[13],"Procedure: Blood Draw",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jason H Karnes, PharmD, PhD","CONTACT","520-626-1447","karnes@pharmacy.arizona.edu",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Talin A Robinson-Catalan, MS","520-278-6114","talinrobinson@arizona.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Banner University Medical Center - Tucson","RECRUITING","Tucson","Arizona","85721","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-110.92648,32.22174,{"lat":42,"lon":41},[45],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jason H Karnes","Assistant Professor",[51],{"name":52,"class":6},"American College of Clinical Pharmacy","100264080","pharmacogenomics-of-heparin-induced-thrombocytopenia-100264080",false,"NCT02717039","Pharmacogenomics of Heparin-Induced Thrombocytopenia","PHIT","Inclusion Criteria:\n\n* 18 years of age or older\n* Ability to give informed consent\n* Have undergone testing for heparin\u002FPF4 antibody with or without SRA testing for HIT\n* Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Pregnancy\n* Hemoglobin less than 9 mg\u002FdL (for larger 5 ounce blood draw)\n* Known Human Immunodeficiency Virus (HIV) infection\n* Inability to give informed consent","ALL","18 Years",{"count":63,"type":64},125,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.",[68],"Heparin-induced Thrombocytopenia","2024-06-25",{"date":71,"type":72},"2024-06-27","ACTUAL",{"date":74,"type":72},"2016-03",{"date":76,"type":64},"2026-07",{"name":5,"class":6},1]